Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches

Background: the rapid progress of proteomics over the past years has allowed the discovery of a large number of potential biomarker candidates to improve early tumor diagnosis and therapeutic response,thus being further integrated into clinical environment. high grade gliomas represent one of the most aggressive and treatment-resistant types of human brain cancer,with approximately 9-12 months median survival rate for patients with grade iv glioma (glioblastoma). using state-of-the-art proteomics technologies,we have investigated the proteome profile for glioblastoma patients in order to identify a novel protein biomarker panel that could discriminate glioblastoma patients from controls and increase diagnostic accuracy.results: in this study,seldi-tof ms technology was used to screen potential protein patterns in glioblastoma patients serum; furthermore,lc-ms/ms technology was applied to identify the candidate biomarkers peaks. through these proteomic approaches,three proteins s100a8,s100a9 and cxcl4 were selected as putative biomarkers and confirmed by elisa. next step was to validate the above mentioned molecules as biomarkers through identification of protein expression by western blot in tumoral versus peritumoral tissue.conclusions: proteomic technologies have been used to investigate the protein profile of glioblastoma patients and established several potential diagnostic biomarkers. while it is unlikely for a single biomarker to be highly effective for glioblastoma diagnostic,our data proposed an alternative and efficient approach by using a novel combination of multiple biomarkers. © 2014 popescu et al.biomed central ltd.